Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancer.

Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancer. Gynecol Oncol. 2023 Oct; 177:20-31.

View in: PubMed

subject areas

Abdominal Pain
Antineoplastic Combined Chemotherapy Protocols
B7-H1 Antigen
Female
Humans
Ovarian Neoplasms
Patient Reported Outcome Measures
Quality of Life

authors with profiles

Luciana Molinero